Mereo BioPharma Group plc · Healthcare · Biotechnology
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
At close
$0.33
−$0.01 (−1.48%) Close
Pre-market$0.32
−$0.01 (−2.29%) 7:02 AM ET
Prev closePrevC$0.34
OpenOpen$0.33
Day highHigh$0.34
Day lowLow$0.33
VolumeVol1,928
Avg volAvgVol1,536,383
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$54.08M
Sector
Healthcare
AI report sections
MIXED
MREO
Mereo BioPharma Group plc
Mereo BioPharma’s share price is trading near the low end of its 52-week range after steep 1–6 month declines, with momentum indicators pointing to a market under pressure. Technical signals show persistent downside trend well below key moving averages and within a bearish Keltner and Ichimoku configuration, while short interest and short volume are elevated enough to indicate notable skepticism. The lack of disclosed financial fundamentals in the available data and a predominantly negative recent news backdrop related to legal investigations further underscores a cautious risk profile.
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO
Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary case involves Soleno Therapeutics, where investors who purchased stock between March 26, 2025 and November 4, 2025 may be entitled to compensation. The lawsuit alleges Soleno made false statements about safety concerns related to its DCCR drug candidate, including fluid retention issues in clinical trials, which posed greater risks than disclosed and reduced commercial viability. The lead plaintiff deadline is May 5, 2026.
SLNOCOTYMREOsecurities class actionSoleno TherapeuticsDCCR drugclinical trial safetyinvestor compensation
Sentiment note
Mentioned as subject of a securities class action lawsuit with a final deadline of April 6, targeting investors with losses exceeding $100K, indicating significant alleged investor harm.
Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor Harm
A class action lawsuit has been filed against Mereo BioPharma Group plc alleging that the company made materially false and misleading statements regarding its Phase 3 ORBIT and COSMIC clinical programs, which failed to meet their primary endpoints. Investors who purchased Mereo securities between June 5, 2023 and December 26, 2025 are encouraged to join the case, with a lead plaintiff deadline of April 6, 2026.
The company is accused of providing false and misleading statements about clinical trial results while concealing material adverse facts. The Phase 3 ORBIT and COSMIC programs failed to meet primary endpoints, resulting in significant investor losses and a securities fraud class action lawsuit.
NegativeGlobeNewswire Inc.• Pomerantz Llp
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines – MREO
Pomerantz LLP has filed a class action lawsuit against Mereo BioPharma Group plc alleging securities fraud. The lawsuit stems from Mereo's announcement on December 29, 2025, that its Phase 3 Orbit and Cosmic studies failed to meet primary endpoints, causing the stock to plummet 87.7% to $0.29 per share. Investors have until April 6, 2026, to request Lead Plaintiff status.
The company's Phase 3 clinical trials (Orbit and Cosmic studies) failed to meet primary endpoints, resulting in an 87.7% stock price decline. A class action lawsuit has been filed alleging securities fraud, indicating potential misrepresentation or failure to disclose material information about trial progress.
Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor Harm
A class action lawsuit has been filed against Mereo BioPharma Group plc alleging that the company made materially false and misleading statements regarding its Phase 3 ORBIT and COSMIC clinical programs, which failed to meet their primary endpoints. Investors who purchased Mereo securities between June 5, 2023 and December 26, 2025 are encouraged to join the case, with a lead plaintiff deadline of April 6, 2026.
The company is accused of providing false and misleading statements to investors while concealing material adverse facts about failed Phase 3 clinical trials (ORBIT and COSMIC programs), which did not meet their primary endpoints. This represents significant corporate misconduct and investor harm.
Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor Harm
A class action lawsuit has been filed against Mereo BioPharma Group plc alleging that the company made materially false and misleading statements regarding its Phase 3 ORBIT and COSMIC clinical programs, which failed to meet their primary endpoints. Investors who purchased Mereo securities between June 5, 2023 and December 26, 2025 are encouraged to join the case, with a lead plaintiff deadline of April 6, 2026.
The company is accused of providing false and misleading statements about clinical trial results while concealing material adverse facts. The failure of Phase 3 ORBIT and COSMIC programs to meet primary endpoints represents significant setbacks for the company's pipeline and investor confidence.
NegativeGlobeNewswire Inc.• Holzer & Holzer, Llc
Holzer & Holzer, LLC Reminds Investors of April 6, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against BlackRock TCP Capital Corp. (TCPC), Mereo BioPharma Group plc (MREO), POMDOCTOR LIMITED (POM), and Ultragenyx Pharmaceutical Inc. (RARE)
Law firm Holzer & Holzer, LLC announced April 6, 2026 lead plaintiff deadlines for shareholder class action lawsuits against BlackRock TCP Capital Corp., Mereo BioPharma Group plc, POMDOCTOR LIMITED, and Ultragenyx Pharmaceutical Inc., alleging materially false statements and/or failure to disclose material facts. Investors who purchased shares during specified periods and suffered losses are encouraged to seek legal representation.
Defendant in class action alleging false statements regarding setrusumab's ability to achieve statistical significance in clinical studies, suggesting misleading disclosures about drug efficacy.
NegativeGlobeNewswire Inc.• Rosen Law Firm
MREO DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MREO
Rosen Law Firm reminds investors in Mereo BioPharma Group plc (NASDAQ: MREO) of the April 6, 2026 lead plaintiff deadline for a securities class action. The lawsuit alleges that Mereo provided misleading statements about Phase 3 clinical trials for setrusumab, expressing confidence in the drug's efficacy while concealing that the trials failed to meet their primary endpoints, causing investors to purchase shares at artificially inflated prices.
MREOsecurities class actionclinical trial failuremisleading statementslead plaintiff deadlinesetrusumabOsteogenesis Imperfecta
Sentiment note
The company is the subject of a securities class action lawsuit alleging material misrepresentation regarding Phase 3 clinical trial results. Defendants allegedly made false positive statements about setrusumab's efficacy while concealing that both ORBIT and COSMIC trials failed to meet primary endpoints, resulting in investor losses from artificially inflated stock prices.
Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor Harm
A class action lawsuit has been filed against Mereo BioPharma Group plc alleging that the company made materially false and misleading statements to investors regarding its Phase 3 ORBIT and COSMIC clinical programs, which failed to meet their primary endpoints. The lawsuit covers investors who purchased Mereo securities between June 5, 2023 and December 26, 2025, with a lead plaintiff deadline of April 6, 2026.
The company is accused of providing false and misleading statements about clinical trial programs while concealing material adverse facts. Both Phase 3 trials (ORBIT and COSMIC) failed to meet primary endpoints, resulting in significant investor losses and a securities fraud class action lawsuit.
NegativeGlobeNewswire Inc.• Holzer & Holzer, Llc
Holzer & Holzer, LLC Reminds Investors of April 6, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against BlackRock TCP Capital Corp. (TCPC), Mereo BioPharma Group plc (MREO), POMDOCTOR LIMITED (POM), and Ultragenyx Pharmaceutical Inc. (RARE)
Law firm Holzer & Holzer reminds investors of April 6, 2026 deadlines to seek lead plaintiff status in shareholder class action lawsuits against BlackRock TCP Capital Corp., Mereo BioPharma Group plc, POMDOCTOR LIMITED, and Ultragenyx Pharmaceutical Inc. The lawsuits allege materially false statements and/or failure to disclose material facts regarding investment valuations, clinical trial results, and fraudulent stock promotion schemes.
Subject of class action lawsuit alleging false statements about setrusumab's ability to achieve statistical significance in clinical studies (ORBIT and COSMIC) between June 2023 and December 2025.
NegativeGlobeNewswire Inc.• Rosen Law Firm
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MREO
Rosen Law Firm is encouraging investors who purchased shares of Mereo BioPharma Group plc (MREO) between June 5, 2023 and December 26, 2025 to join a securities class action lawsuit. The lawsuit alleges that Mereo provided misleading statements about Phase 3 clinical trials for setrusumab, expressing confidence in the drug's success while concealing that the trials failed to meet their primary endpoints, causing investors to purchase shares at artificially inflated prices.
The company is the subject of a securities class action lawsuit alleging material misrepresentation regarding Phase 3 clinical trial results for setrusumab. Defendants allegedly made false positive statements about trial outcomes while concealing that the trials failed to meet primary endpoints, resulting in artificially inflated stock prices and investor losses.
Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor Harm
A class action lawsuit has been filed against Mereo BioPharma Group plc alleging that the company made materially false and misleading statements regarding its Phase 3 ORBIT and COSMIC clinical programs, which failed to meet their primary endpoints. Investors who purchased Mereo securities between June 5, 2023 and December 26, 2025 are encouraged to join the case, with a lead plaintiff deadline of April 6, 2026.
The company is accused of providing false and misleading statements about clinical trial results while concealing material adverse facts. The failure of Phase 3 ORBIT and COSMIC programs to meet primary endpoints represents significant setbacks for the company's pipeline and investor confidence.
NegativeGlobeNewswire Inc.• Pomerantz Llp
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines – MREO
Pomerantz Law Firm has filed class action lawsuits against Mereo BioPharma Group plc, Snowflake Inc., and Navan, Inc. for alleged securities fraud. The primary focus is on Mereo, whose stock plummeted 87.7% after announcing that its Phase 3 clinical trials (Orbit and Cosmic studies) failed to meet primary endpoints in December 2025. Investors who purchased securities during the class period have until April 6, 2026, to join the lawsuit.
Company's stock experienced catastrophic declines (42.52% on July 10, 2025, and 87.7% on December 29, 2025) following failed Phase 3 clinical trials for UX143 (setrusumab). The failure to meet primary endpoints in both Orbit and Cosmic studies, combined with the class action lawsuit alleging securities fraud, indicates severe negative developments.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
